Astria Therapeutics Inc (NASDAQ: ATXS)’s stock price has plunge by 1.97relation to previous closing price of 10.14. Nevertheless, the company has seen a -1.52% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-12-03 that BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria’s common stock on December 2, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gra.
Is It Worth Investing in Astria Therapeutics Inc (NASDAQ: ATXS) Right Now?
The 36-month beta value for ATXS is at 0.67. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ATXS is 48.25M, and currently, shorts hold a 6.01% of that float. The average trading volume for ATXS on December 05, 2024 was 310.96K shares.
ATXS’s Market Performance
The stock of Astria Therapeutics Inc (ATXS) has seen a -1.52% decrease in the past week, with a -10.17% drop in the past month, and a -7.01% fall in the past quarter. The volatility ratio for the week is 4.16%, and the volatility levels for the past 30 days are at 6.50% for ATXS. The simple moving average for the last 20 days is 0.18% for ATXS stock, with a simple moving average of -6.94% for the last 200 days.
Analysts’ Opinion of ATXS
Many brokerage firms have already submitted their reports for ATXS stocks, with TD Cowen repeating the rating for ATXS by listing it as a “Buy.” The predicted price for ATXS in the upcoming period, according to TD Cowen is $35 based on the research report published on July 29, 2024 of the current year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see ATXS reach a price target of $18. The rating they have provided for ATXS stocks is “Outperform” according to the report published on March 28th, 2023.
ATXS Trading at -6.04% from the 50-Day Moving Average
After a stumble in the market that brought ATXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.82% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 4.16%, as shares sank -14.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.15% lower at present.
During the last 5 trading sessions, ATXS fell by -3.24%, which changed the moving average for the period of 200-days by -21.73% in comparison to the 20-day moving average, which settled at $10.31. In addition, Astria Therapeutics Inc saw 34.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATXS starting from Morabito Christopher, who sale 10,000 shares at the price of $13.59 back on Apr 01 ’24. After this action, Morabito Christopher now owns 0 shares of Astria Therapeutics Inc, valued at $135,939 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the Director of Astria Therapeutics Inc, purchase 2,481,350 shares at $12.09 during a trade that took place back on Feb 01 ’24, which means that PERCEPTIVE ADVISORS LLC is holding 4,873,721 shares at $29,999,522 based on the most recent closing price.
Stock Fundamentals for ATXS
The total capital return value is set at -0.29. Equity return is now at value -38.03, with -36.02 for asset returns.
Currently, EBITDA for the company is -83.03 million with net debt to EBITDA at 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.38.
Conclusion
In conclusion, Astria Therapeutics Inc (ATXS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
